(Q33226589)

24 July 2017

The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance (English)

1 reference

24 July 2017

0 references

1 reference

Cilloni D

1

1 reference

24 July 2017

Messa F

2

1 reference

24 July 2017

Arruga F

3

1 reference

24 July 2017

Defilippi I

4

1 reference

24 July 2017

Morotti A

5

1 reference

24 July 2017

Messa E

6

1 reference

24 July 2017

Carturan S

7

1 reference

24 July 2017

Giugliano E

8

1 reference

24 July 2017

Pautasso M

9

1 reference

24 July 2017

Bracco E

10

1 reference

24 July 2017

Rosso V

11

1 reference

24 July 2017

Sen A

12

1 reference

24 July 2017

Martinelli G

13

1 reference

24 July 2017

Baccarani M

14

1 reference

24 July 2017

Saglio G

15

1 reference

24 July 2017

1 January 2006

1 reference

24 July 2017

1 reference

24 July 2017

20

1 reference

24 July 2017

61-67

1 reference

24 July 2017

1

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403998

24 July 2017

0 references

cites work

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403998

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403998

Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403998

Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403998

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403998

Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403998

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403998

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403998

Missing pieces in the NF-kappaB puzzle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403998

NF-kappaB in cancer: a marked target

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403998

Nuclear transcription factor-kappaB as a target for cancer drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403998

Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403998

Expression of constitutively active nuclear-kappa B RelA transcription factor in blasts of acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403998

Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403998

Nuclear factor-kappaB modulation as a therapeutic approach in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403998

Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403998

NF-kappaB at the crossroads of life and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403998

The IKK/NF-kappa B pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403998

NF-kappa B as a therapeutic target in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403998

NF-kappaB signaling and human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403998

Activators and target genes of Rel/NF-kappaB transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403998

The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403998

Direct Phosphorylation of IB by IKK and IKK: Discrimination Between Free and NF-B-Bound Substrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403998

Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403998

Inactivation of NF-kappaB-dependent cell survival, a novel mechanism for the proapoptotic function of c-Abl

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403998

c-Abl: activation and nuclear targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403998

The Abl family kinases: mechanisms of regulation and signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403998

A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403998

Increased IkappaB kinase activity is associated with activated NF-kappaB in acute myeloid blasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403998

inferred from DOI database lookup

7 January 2021

based on heuristic

Natural resistance of acute myeloid leukemia cell lines to mitoxantrone is associated with lack of apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403998

inferred from DOI database lookup

7 January 2021

based on heuristic

Novel therapies for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403998

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.LEU.2403998

1 reference

Dimensions Publication ID

24 July 2017

0 references

1 reference